Wills Eye Retina specialists are in the forefront of research efforts, participating in multiple retina studies for macular degeneration, diabetic retinopathy, and a variety of other retinal conditions. We have been the principal investigators of most of the major retina studies.
For more information about a
Retina Study,
call 267-541-3016
Longer-Acting Pharmacologic Agents: These new medical compounds are being studied to determine their efficacy and safety in comparison to the current standard anti-vascular endothelial growth factor (VEGF) agents. Administered by intravitreal injection, they may potentially achieve a longer therapeutic effect.
Port Delivery System (PDS): PDS is a small surgical implant that is intended to slowly release a well-established anti-VEGF medication. The aim is to reduce the need for intravitreal injections and the implant can be refilled with a special syringe in the office setting.
Anti-Inflammation: Inflammation is implicated in the pathophysiology of atrophy and vision cell loss in advanced dry AMD. Pharmacologic agents designed to block or modulate various parts of the inflammation process may slow the progression and development of geographic atrophy.
Cell Based: Cell-based therapy involves the subretinal surgical delivery of stem cells to replace or regenerate dysfunctional cells and tissue caused by dry AMD.
Longer-Acting Pharmacologic Agents: These new medical compounds are being studied to determine their efficacy and safety in comparison to the current standard anti-vascular endothelial growth factor (VEGF) agents. Administered by intravitreal injection, they may potentially achieve a longer therapeutic effect.
These are studies to see If medications delivered by intravitreal injection, suprachoroidal injections, port delivery systems, or topical drops can slow down the progression of diabetic retinopathy or the effect of diabetes on the retinal blood vessels.
Port Delivery System (PDS): PDS is a small surgical implant that is intended to slowly release a well-established anti-VEGF medication. The aim is to reduce the need for intravitreal injections and the implant can be refilled with a special syringe in the office setting.
Longer-Acting Pharmacologic Agents: These new medical compounds are being studied to determine their efficacy and safety in comparison to the current standard anti-vascular endothelial growth factor (VEGF) agents. Administered by intravitreal injection, they may potentially achieve a longer therapeutic effect.
These studies target specific mutations found in certain inherited retinal diseases.
These are studies to improve aspects of diseases that result in inflammation in the eye.
For additional information, please see our FAQs page , call, or send a message below.
